RUNX3 and liver disorder: To address this knowledge gap, we investigated RUNX3 methylation levels in a cohort exposed to both AFB1 and HBV, aiming to evaluate its potential as a sensitive biomarker for monitoring early liver disease caused by co-exposure to AFB1 and HBV.